Parametric Portfolio Associates’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Parametric Portfolio Associates’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,342	Closed	-$44K	–	3982
2020 Q2	$44K	Buy	+4,342	New	+$39.9K	﹤0.01%	3874
2020 Q1	–	Sell	-4,160	Closed	-$36K	–	4030
2019 Q4	$36K	Buy	+4,160	New	+$23.3K	﹤0.01%	3939
2019 Q3	–	Sell	-3,696	Closed	-$61K	–	4012
2019 Q2	$61K	Buy	3,696 +319	+9%	+$5.54K	﹤0.01%	3898
2019 Q1	$56K	Buy	+3,377	New	+$48.6K	﹤0.01%	3882
2018 Q4	–	Sell	-3,601	Closed	-$144K	–	3973
2018 Q3	$144K	Buy	+3,601	New	+$102K	﹤0.01%	3813
2016 Q2	–	Sell	-17,275	Closed	-$372K	–	3956
2016 Q1	$372K	Buy	+17,275	New	+$366K	﹤0.01%	3491

Other funds holding MRNS

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return